Compare · Head-to-head
Angiotensin 1-7 vs MK-677.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Angiotensin 1-7, then use the table to confirm fit.
Angiotensin 1-7 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Angiotensin 1-7
Protective renin-angiotensin-system peptide studied for vascular, anti-inflammatory, and anti-fibrotic effects.
01 · At a glance
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Primary fit | longevity & anti-aging and immune support comparisons | muscle growth & strength and longevity & anti-aging comparisons |
| Evidence | Tier B | Tier C |
| Risk | low | med-high |
| Experience level | advanced | advanced |
| Budget tier | premium | mid |
| Administration route | intravenous, subcutaneous | oral |
02 · Use case & timing
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Goal fit | Longevity & Anti-Aging, Immune Support | Muscle Growth & Strength, Longevity & Anti-Aging, GH Axis Optimization |
| What users compare it for | Potential endothelial, anti-inflammatory, and anti-fibrotic benefits in vascular and pulmonary research settings. | Increased GH/IGF-1 signaling, appetite rise, and potential lean-mass increase in some human studies. |
| Onset timeline | Hemodynamic effects can appear quickly during infusion; structural outcomes are studied over longer periods. | GH rises acutely; IGF-1 and body-composition effects are tracked over weeks to months. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Adverse effects | Main practical risk is hypotension or reflex tachycardia, especially in combination with other RAAS-active therapies. | Edema, increased appetite, insulin resistance, elevated fasting glucose, joint discomfort, and possible cardiovascular safety concerns. |
| Contraindications | Avoid in hypotension, volume depletion, and use caution with ACE inhibitors or ARBs. | Use caution in diabetes, insulin resistance, edema-prone states, heart failure risk, and active malignancy. |
| Interaction notes | Likely additive blood-pressure lowering with ACE inhibitors, ARBs, and other vasodilating strategies. | Combining with other GH-axis compounds increases endocrine complexity and may worsen glucose control. |
| Regulatory status | Investigational | Not approved |
| FDA flag | No current flag noted | FDA compounding caution |
| WADA status | Not listed | WADA S2 |
04 · Age & monitoring
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54 |
| Life-stage note | Not yet documented | Most often discussed for younger and midlife adults, but metabolic and fluid-retention risks narrow the fit quickly with age. |
| Monitoring burden | Not specified | high |
| Follow-up cadence | Not yet documented | More frequent early follow-up, then reassessment every few months if continued. |
05 · Cost & sourcing
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | No reliable estimate yet |
| Estimated monthly cost | No reliable estimate yet | No reliable estimate yet |
| Cost confidence | No estimate | No estimate |
06 · Before you buy
| Decision factor | Angiotensin 1-7 | MK-677 |
|---|---|---|
| Tracked vendor listings | 0 listings | 0 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.